Labiotech.eu

TEVA Eagle Pharmaceuticals leukemia bendamustine

News and Trends 17 Apr 2015

Teva took the first step to get the approval of its new leukemia treatment

FDA accepted Teva Pharma’s New Drug Application (NDA) for a liquid bendamustine hydrochloride (HCl) rapid infusion product. The drug, developed with Eagle Pharmaceuticals is now waiting for the Prescription Drug User Fee Act (PDUFA), which is expected for December 2015. In the meantime, the Israeli company remains unstoppable after a great begining of the month on […]

April 17, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 17 Apr 2015

Merck Serono bets on Oncology with the appointment of Dr. Alise Reicin

Merck Serono appointed Dr. Alise Reicin as Senior Vice President, Head of Global Clinical Development. The appointment is yet another example of Merck’s clear interest in oncology and immunology, two fields in which Dr. Reicin expertised. Dr. Reicin will also bring extensive research and early/late clinical development expertise to Merck Serono. In her role as […]

April 17, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 16 Apr 2015

Histalim, already 10 years committed to Histology

In the prestigious Fabre Museum of Montpelier (France), Thursday, April 9, 2015, Histalim organized for his birthday, an afternoon of table speeches around bioservices and also an evening with contemporary art exhibition and concert. Histalim, founded in June 2005, provides services around histology to different players in the pharmaceutical and medical industry and agri-food research. […]

April 16, 2015 - 5 minutesmins - By Cédric Brock

News and Trends 16 Apr 2015

The first-in-human Phase I trial for a treatment against glaucoma core

Isarna Therapeutics has initiated Phase I clinical trial with ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta (TGF-ß2) to treat advanced glaucoma. This first-in-human Phase I trial, conducted at the University Hospitals of Mainz and Tuebingen, Germany, is designed to evaluate the safety and long-term tolerability of ISTH0036 in patients with advanced glaucoma […]

April 16, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 16 Apr 2015

Wilson Therapeutics on its way to cure Wilson disease

Wilson Therapeutics has closed a €37.4M Series B financing to advance its late-stage development program for Wilson’s disease. The company will present its ongoing Phase II trial of WTX101-201, the company’s treatment for this disease, at the upcoming 50th International Liver Congress 2015. Approximately 1 in 15000 people worldwide have Wilson Disease, a rare genetic disorder that prevents the […]

April 16, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 16 Apr 2015

Bayer Healthcare invests €94 Million in its Hemophilia pipeline

Bayer HealthCare, a subgroup of Bayer AG, is one of the world’s leading, innovative companies in the healthcare and medical products industry. Yesterday, the company announced a €94M investment in its Berkeley (California) manufacturing site to build a product testing facility that will support the next generation of treatments for patients with hemophilia A. David […]

April 16, 2015 - 2 minutesmins - By Joachim Eeckhout

final sterilization proteins solution sanofi pasteur

News and Trends 16 Apr 2015

The challenge of terminal sterilization of Proteins

The production of biologicals is an important challenge for the industry. Today, very often, the only way to have a sterile final product is to, first, use sterile components and then, launch the production in a fully aseptic manufacturing facility. What if we could terminally sterilize the protein-based outcome once produced? More and more biologicals are brought to the market, […]

April 16, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 16 Apr 2015

flash4science, the life science private shopping club

Any scientist knows how expensive purchasing new equipment can be. However, one platform, flash4Science, in particular caught our attention. The company located in Germany has set itself an interesting challenge as it tries to combine life sciences and private shopping together. Two domains, which, on paper, seem completely incompatible! It is the world’s first biotech […]

April 16, 2015 - 2 minutesmins - By Alexandre Lowrey

News and Trends 15 Apr 2015

Synthetic bio: one single Grapefruit to produce one Million liters of Juice

The Austrian Centre of Industrial Biotechnology (acib), using synthetic biology technology, developed a new method to produce Nootkatone, an expensive grapefruit aroma. The biotechnological process uses cheap sugar as substrate for a “turbo-yeast”. The extremely expensive substance is used in soft drinks, pharmaceutical products or even as an insect repellent, and it is found only […]

April 15, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 15 Apr 2015

Heart Metabolics bargain with the FDA for a single Phase III

Heart Metabolics received an agreement letter from the FDA related to the company’s proposed phase III trial Special Protocol Assessment (SPA) request. The FDA has agreed to a single, randomized, pivotal Phase III trial of 350 patients evaluating perhexiline for the treatment of moderate-to-severe hypertrophic cardiomyopathy (HCM). The company, focused on the development of drugs […]

April 15, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 15 Apr 2015

AstraZeneca avoided a public crisis of its marketed diabetes treatment

Last week, FDA expressed its concerns about AstraZeneca’s treatment for type 2 diabetes, Onglyza. According to Reuters, FDA found “significant or near significant” increase of death risk. However, the agency also admits that the cause of death is multifactorial and could not be directly related to AstraZeneca’s treatment. The drug was developed as a result […]

April 15, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 15 Apr 2015

Will the roads of the future be paved with microalgae?

In contrast to first generation biofuels, where edible plants were suggested to be grown to obtain oil, microalgae raise as a very promising source alternative to fossil fuels. For the first time, they have been used to make bio-bitumen. Some French public institutes (Centre National de la Recherche Scientifique, Université de Nantes, Ecole des Mines de Nantes) in partnership […]

April 15, 2015 - 2 minutesmins - By Joachim Eeckhout

Resources

Categories

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Teva took the first step to get the approval of its new leukemia treatment

Merck Serono bets on Oncology with the appointment of Dr. Alise Reicin

Histalim, already 10 years committed to Histology

The first-in-human Phase I trial for a treatment against glaucoma core

Wilson Therapeutics on its way to cure Wilson disease

Bayer Healthcare invests €94 Million in its Hemophilia pipeline

The challenge of terminal sterilization of Proteins

flash4science, the life science private shopping club

Synthetic bio: one single Grapefruit to produce one Million liters of Juice

Heart Metabolics bargain with the FDA for a single Phase III

AstraZeneca avoided a public crisis of its marketed diabetes treatment

Will the roads of the future be paved with microalgae?

Subscribe to our newsletter to get the latest biotech news!

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!